OmniAb to Hold Research & Technology Virtual Event on November 9
October 12 2023 - 8:00AM
Business Wire
Webcast to include an update on latest
technology offerings and third quarter 2023 financial
results
OmniAb, Inc. (Nasdaq: OABI) today announced it will hold
a virtual Research & Technology event on Thursday, November 9
beginning at 11:00 a.m. Eastern time. The event is expected to last
approximately two hours and will include a review of the company’s
latest technology offerings and financial results for the three and
nine months ended September 30, 2023, which will be announced
earlier that morning.
Matt Foehr, Chief Executive Officer, will be joined by members
of OmniAb’s senior management team, with a Q&A session to
follow management’s presentations.
The webcast and replay, including audio, video and presentation
slides, will be available on the Investors portion of OmniAb’s
website. Additional information about speakers and their
presentations, as well as instructions about how to participate
will be announced at a later date.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that have been genetically
modified to generate antibodies with human sequences to facilitate
development of human therapeutic candidates. OmniFlic® (transgenic
rat) and OmniClic® (transgenic chicken) address industry needs for
bispecific antibody applications though a common light chain
approach, and OmniTaur™ features unique structural attributes of
cow antibodies for complex targets. We believe the OmniAb animals
comprise the most diverse host systems available in the industry
and they are optimally leveraged through computational antigen
design and immunization methods, paired with high-throughput single
B cell phenotypic screening and mining of next-generation
sequencing datasets with custom algorithms to identify fully human
antibodies with superior performance and developability
characteristics. These proprietary technologies are joined with and
leverage OmniDeep™, which is a suite of in silico tools for
therapeutic discovery and optimization that are woven throughout
OmniAb’s various technologies and capabilities. Additionally, an
established core competency focused on ion channels and
transporters further differentiates OmniAb’s technology and creates
opportunities in many emerging target classes. OmniAb antibodies
have been leveraged across modalities, including bispecific
antibodies, antibody-drug conjugates and others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting-edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231012819254/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@OmniAb.com Twitter (X)
@OmniAbTech
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Sep 2024 to Oct 2024
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Oct 2023 to Oct 2024